Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: TechNavio | PRODUCT CODE: 1234264

Cover Image

PUBLISHER: TechNavio | PRODUCT CODE: 1234264

Global Bispecific Antibodies for Cancer Market 2023-2027

PUBLISHED:
PAGES: 155 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
PDF (Single User License)
USD 2500
PDF (Enterprise License)
USD 4000

Add to Cart

Technavio has been monitoring the bispecific antibodies for cancer market and is forecast to grow by $400.72 mn during 2022-2027, accelerating at a CAGR of 8.82% during the forecast period. Our report on the bispecific antibodies for cancer market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increasing prevalence of cancer, advantages of bispecific antibodies over monoclonal antibodies, and strong pipeline.

Technavio's bispecific antibodies for cancer market is segmented as below:

By Type

  • CD19 or CD3
  • CD30 or CD16A

By Distribution Channel

  • Hospitals
  • Retail pharmacies
  • Online

By Geography

  • North America
  • Europe
  • Asia
  • Rest of World (ROW)

This study identifies the emerging bispecific antibody generation platforms as one of the prime reasons driving the bispecific antibodies for cancer market growth during the next few years. Also, increase in strategic alliances. and strong R&D in China will lead to sizable demand in the market.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on the bispecific antibodies for cancer market covers the following areas:

  • Bispecific antibodies for cancer market sizing
  • Bispecific antibodies for cancer market forecast
  • Bispecific antibodies for cancer market industry analysis

Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading bispecific antibodies for cancer market vendors that include ABL Bio Inc., AFFIMED N.V., Akeso Inc., Amgen Inc., Aptevo Therapeutics Inc., Astellas Pharma Inc., Chugai Pharmaceutical Co. Ltd., Eli Lilly and Co., EPIMAB BIOTHERAPEUTICS INC., F STAR THERAPEUTICS INC., F. Hoffmann La Roche Ltd., Glenmark Pharmaceuticals Ltd., Johnson and Johnson, Mereo BioPharma Group Plc, Merus N.V., Pfizer Inc., Regeneron Pharmaceuticals Inc., TG Therapeutics Inc., Xencor Inc., and Y mAbs Therapeutics Inc. Also, the bispecific antibodies for cancer market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Product Code: IRTNTR72677

Table of Contents

1 Executive Summary

  • 1.1 Market overview
  • Exhibit 01: Executive Summary - Chart on Market Overview
  • Exhibit 02: Executive Summary - Data Table on Market Overview
  • Exhibit 03: Executive Summary - Chart on Global Market Characteristics
  • Exhibit 04: Executive Summary - Chart on Market by Geography
  • Exhibit 05: Executive Summary - Chart on Market Segmentation by Type
  • Exhibit 06: Executive Summary - Chart on Market Segmentation by Distribution Channel
  • Exhibit 07: Executive Summary - Chart on Incremental Growth
  • Exhibit 08: Executive Summary - Data Table on Incremental Growth
  • Exhibit 09: Executive Summary - Chart on Vendor Market Positioning

2 Market Landscape

  • 2.1 Market ecosystem
  • Exhibit 10: Parent market
  • Exhibit 11: Market Characteristics

3 Market Sizing

  • 3.1 Market definition
  • Exhibit 12: Offerings of vendors included in the market definition
  • 3.2 Market segment analysis
  • Exhibit 13: Market segments
  • 3.3 Market size 2022
  • 3.4 Market outlook: Forecast for 2022-2027
  • Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million)
  • Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
  • Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
  • Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)

4 Historic Market Size

  • 4.1 Global bispecific antibodies for cancer market 2017 - 2021
  • Exhibit 18: Historic Market Size - Data Table on Global bispecific antibodies for cancer market 2017 - 2021 ($ million)
  • 4.2 Type Segment Analysis 2017 - 2021
  • Exhibit 19: Historic Market Size - Type Segment 2017 - 2021 ($ million)
  • 4.3 Distribution channel Segment Analysis 2017 - 2021
  • Exhibit 20: Historic Market Size - Distribution channel Segment 2017 - 2021 ($ million)
  • 4.4 Geography Segment Analysis 2017 - 2021
  • Exhibit 21: Historic Market Size - Geography Segment 2017 - 2021 ($ million)
  • 4.5 Country Segment Analysis 2017 - 2021
  • Exhibit 22: Historic Market Size - Country Segment 2017 - 2021 ($ million)

5 Five Forces Analysis

  • 5.1 Five forces summary
  • Exhibit 23: Five forces analysis - Comparison between 2022 and 2027
  • 5.2 Bargaining power of buyers
  • Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2022 and 2027
  • 5.3 Bargaining power of suppliers
  • Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2022 and 2027
  • 5.4 Threat of new entrants
  • Exhibit 26: Threat of new entrants - Impact of key factors in 2022 and 2027
  • 5.5 Threat of substitutes
  • Exhibit 27: Threat of substitutes - Impact of key factors in 2022 and 2027
  • 5.6 Threat of rivalry
  • Exhibit 28: Threat of rivalry - Impact of key factors in 2022 and 2027
  • 5.7 Market condition
  • Exhibit 29: Chart on Market condition - Five forces 2022 and 2027

6 Market Segmentation by Type

  • 6.1 Market segments
  • Exhibit 30: Chart on Type - Market share 2022-2027 (%)
  • Exhibit 31: Data Table on Type - Market share 2022-2027 (%)
  • 6.2 Comparison by Type
  • Exhibit 32: Chart on Comparison by Type
  • Exhibit 33: Data Table on Comparison by Type
  • 6.3 CD19 or CD3 - Market size and forecast 2022-2027
  • Exhibit 34: Chart on CD19 or CD3 - Market size and forecast 2022-2027 ($ million)
  • Exhibit 35: Data Table on CD19 or CD3 - Market size and forecast 2022-2027 ($ million)
  • Exhibit 36: Chart on CD19 or CD3 - Year-over-year growth 2022-2027 (%)
  • Exhibit 37: Data Table on CD19 or CD3 - Year-over-year growth 2022-2027 (%)
  • 6.4 CD30 or CD16A - Market size and forecast 2022-2027
  • Exhibit 38: Chart on CD30 or CD16A - Market size and forecast 2022-2027 ($ million)
  • Exhibit 39: Data Table on CD30 or CD16A - Market size and forecast 2022-2027 ($ million)
  • Exhibit 40: Chart on CD30 or CD16A - Year-over-year growth 2022-2027 (%)
  • Exhibit 41: Data Table on CD30 or CD16A - Year-over-year growth 2022-2027 (%)
  • 6.5 Market opportunity by Type
  • Exhibit 42: Market opportunity by Type ($ million)
  • Exhibit 43: Data Table on Market opportunity by Type ($ million)

7 Market Segmentation by Distribution Channel

  • 7.1 Market segments
  • Exhibit 44: Chart on Distribution Channel - Market share 2022-2027 (%)
  • Exhibit 45: Data Table on Distribution Channel - Market share 2022-2027 (%)
  • 7.2 Comparison by Distribution Channel
  • Exhibit 46: Chart on Comparison by Distribution Channel
  • Exhibit 47: Data Table on Comparison by Distribution Channel
  • 7.3 Hospitals - Market size and forecast 2022-2027
  • Exhibit 48: Chart on Hospitals - Market size and forecast 2022-2027 ($ million)
  • Exhibit 49: Data Table on Hospitals - Market size and forecast 2022-2027 ($ million)
  • Exhibit 50: Chart on Hospitals - Year-over-year growth 2022-2027 (%)
  • Exhibit 51: Data Table on Hospitals - Year-over-year growth 2022-2027 (%)
  • 7.4 Retail pharmacies - Market size and forecast 2022-2027
  • Exhibit 52: Chart on Retail pharmacies - Market size and forecast 2022-2027 ($ million)
  • Exhibit 53: Data Table on Retail pharmacies - Market size and forecast 2022-2027 ($ million)
  • Exhibit 54: Chart on Retail pharmacies - Year-over-year growth 2022-2027 (%)
  • Exhibit 55: Data Table on Retail pharmacies - Year-over-year growth 2022-2027 (%)
  • 7.5 Online - Market size and forecast 2022-2027
  • Exhibit 56: Chart on Online - Market size and forecast 2022-2027 ($ million)
  • Exhibit 57: Data Table on Online - Market size and forecast 2022-2027 ($ million)
  • Exhibit 58: Chart on Online - Year-over-year growth 2022-2027 (%)
  • Exhibit 59: Data Table on Online - Year-over-year growth 2022-2027 (%)
  • 7.6 Market opportunity by Distribution Channel
  • Exhibit 60: Market opportunity by Distribution Channel ($ million)
  • Exhibit 61: Data Table on Market opportunity by Distribution Channel ($ million)

8 Customer Landscape

  • 8.1 Customer landscape overview
  • Exhibit 62: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

  • 9.1 Geographic segmentation
  • Exhibit 63: Chart on Market share by geography 2022-2027 (%)
  • Exhibit 64: Data Table on Market share by geography 2022-2027 (%)
  • 9.2 Geographic comparison
  • Exhibit 65: Chart on Geographic comparison
  • Exhibit 66: Data Table on Geographic comparison
  • 9.3 North America - Market size and forecast 2022-2027
  • Exhibit 67: Chart on North America - Market size and forecast 2022-2027 ($ million)
  • Exhibit 68: Data Table on North America - Market size and forecast 2022-2027 ($ million)
  • Exhibit 69: Chart on North America - Year-over-year growth 2022-2027 (%)
  • Exhibit 70: Data Table on North America - Year-over-year growth 2022-2027 (%)
  • 9.4 Europe - Market size and forecast 2022-2027
  • Exhibit 71: Chart on Europe - Market size and forecast 2022-2027 ($ million)
  • Exhibit 72: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
  • Exhibit 73: Chart on Europe - Year-over-year growth 2022-2027 (%)
  • Exhibit 74: Data Table on Europe - Year-over-year growth 2022-2027 (%)
  • 9.5 Asia - Market size and forecast 2022-2027
  • Exhibit 75: Chart on Asia - Market size and forecast 2022-2027 ($ million)
  • Exhibit 76: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
  • Exhibit 77: Chart on Asia - Year-over-year growth 2022-2027 (%)
  • Exhibit 78: Data Table on Asia - Year-over-year growth 2022-2027 (%)
  • 9.6 Rest of World (ROW) - Market size and forecast 2022-2027
  • Exhibit 79: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
  • Exhibit 80: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
  • Exhibit 81: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
  • Exhibit 82: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
  • 9.7 US - Market size and forecast 2022-2027
  • Exhibit 83: Chart on US - Market size and forecast 2022-2027 ($ million)
  • Exhibit 84: Data Table on US - Market size and forecast 2022-2027 ($ million)
  • Exhibit 85: Chart on US - Year-over-year growth 2022-2027 (%)
  • Exhibit 86: Data Table on US - Year-over-year growth 2022-2027 (%)
  • 9.8 Ireland - Market size and forecast 2022-2027
  • Exhibit 87: Chart on Ireland - Market size and forecast 2022-2027 ($ million)
  • Exhibit 88: Data Table on Ireland - Market size and forecast 2022-2027 ($ million)
  • Exhibit 89: Chart on Ireland - Year-over-year growth 2022-2027 (%)
  • Exhibit 90: Data Table on Ireland - Year-over-year growth 2022-2027 (%)
  • 9.9 China - Market size and forecast 2022-2027
  • Exhibit 91: Chart on China - Market size and forecast 2022-2027 ($ million)
  • Exhibit 92: Data Table on China - Market size and forecast 2022-2027 ($ million)
  • Exhibit 93: Chart on China - Year-over-year growth 2022-2027 (%)
  • Exhibit 94: Data Table on China - Year-over-year growth 2022-2027 (%)
  • 9.10 Hungary - Market size and forecast 2022-2027
  • Exhibit 95: Chart on Hungary - Market size and forecast 2022-2027 ($ million)
  • Exhibit 96: Data Table on Hungary - Market size and forecast 2022-2027 ($ million)
  • Exhibit 97: Chart on Hungary - Year-over-year growth 2022-2027 (%)
  • Exhibit 98: Data Table on Hungary - Year-over-year growth 2022-2027 (%)
  • 9.11 India - Market size and forecast 2022-2027
  • Exhibit 99: Chart on India - Market size and forecast 2022-2027 ($ million)
  • Exhibit 100: Data Table on India - Market size and forecast 2022-2027 ($ million)
  • Exhibit 101: Chart on India - Year-over-year growth 2022-2027 (%)
  • Exhibit 102: Data Table on India - Year-over-year growth 2022-2027 (%)
  • 9.12 Market opportunity by geography
  • Exhibit 103: Market opportunity by geography ($ million)
  • Exhibit 104: Data Tables on Market opportunity by geography ($ million)

10 Drivers, Challenges, and Trends

  • 10.1 Market drivers
  • 10.2 Market challenges
  • 10.3 Impact of drivers and challenges
  • Exhibit 105: Impact of drivers and challenges in 2022 and 2027
  • 10.4 Market trends

11 Vendor Landscape

  • 11.1 Overview
  • 11.2 Vendor landscape
  • Exhibit 106: Overview on Criticality of inputs and Factors of differentiation
  • 11.3 Landscape disruption
  • Exhibit 107: Overview on factors of disruption
  • 11.4 Industry risks
  • Exhibit 108: Impact of key risks on business

12 Vendor Analysis

  • 12.1 Vendors covered
  • Exhibit 109: Vendors covered
  • 12.2 Market positioning of vendors
  • Exhibit 110: Matrix on vendor position and classification
  • 12.3 ABL Bio Inc.
  • Exhibit 111: ABL Bio Inc. - Overview
  • Exhibit 112: ABL Bio Inc. - Product / Service
  • Exhibit 113: ABL Bio Inc. - Key offerings
  • 12.4 AFFIMED N.V.
  • Exhibit 114: AFFIMED N.V. - Overview
  • Exhibit 115: AFFIMED N.V. - Product / Service
  • Exhibit 116: AFFIMED N.V. - Key offerings
  • 12.5 Akeso Inc.
  • Exhibit 117: Akeso Inc. - Overview
  • Exhibit 118: Akeso Inc. - Product / Service
  • Exhibit 119: Akeso Inc. - Key offerings
  • 12.6 Amgen Inc.
  • Exhibit 120: Amgen Inc. - Overview
  • Exhibit 121: Amgen Inc. - Product / Service
  • Exhibit 122: Amgen Inc. - Key offerings
  • 12.7 Aptevo Therapeutics Inc.
  • Exhibit 123: Aptevo Therapeutics Inc. - Overview
  • Exhibit 124: Aptevo Therapeutics Inc. - Product / Service
  • Exhibit 125: Aptevo Therapeutics Inc. - Key offerings
  • 12.8 Astellas Pharma Inc.
  • Exhibit 126: Astellas Pharma Inc. - Overview
  • Exhibit 127: Astellas Pharma Inc. - Product / Service
  • Exhibit 128: Astellas Pharma Inc. - Key offerings
  • 12.9 Chugai Pharmaceutical Co. Ltd.
  • Exhibit 129: Chugai Pharmaceutical Co. Ltd. - Overview
  • Exhibit 130: Chugai Pharmaceutical Co. Ltd. - Product / Service
  • Exhibit 131: Chugai Pharmaceutical Co. Ltd. - Key offerings
  • 12.10 Eli Lilly and Co.
  • Exhibit 132: Eli Lilly and Co. - Overview
  • Exhibit 133: Eli Lilly and Co. - Product / Service
  • Exhibit 134: Eli Lilly and Co. - Key offerings
  • 12.11 EPIMAB BIOTHERAPEUTICS INC.
  • Exhibit 135: EPIMAB BIOTHERAPEUTICS INC. - Overview
  • Exhibit 136: EPIMAB BIOTHERAPEUTICS INC. - Product / Service
  • Exhibit 137: EPIMAB BIOTHERAPEUTICS INC. - Key offerings
  • 12.12 F STAR THERAPEUTICS INC.
  • Exhibit 138: F STAR THERAPEUTICS INC. - Overview
  • Exhibit 139: F STAR THERAPEUTICS INC. - Product / Service
  • Exhibit 140: F STAR THERAPEUTICS INC. - Key offerings
  • 12.13 F. Hoffmann La Roche Ltd.
  • Exhibit 141: F. Hoffmann La Roche Ltd. - Overview
  • Exhibit 142: F. Hoffmann La Roche Ltd. - Business segments
  • Exhibit 143: F. Hoffmann La Roche Ltd. - Key news
  • Exhibit 144: F. Hoffmann La Roche Ltd. - Key offerings
  • Exhibit 145: F. Hoffmann La Roche Ltd. - Segment focus
  • 12.14 Glenmark Pharmaceuticals Ltd.
  • Exhibit 146: Glenmark Pharmaceuticals Ltd. - Overview
  • Exhibit 147: Glenmark Pharmaceuticals Ltd. - Product / Service
  • Exhibit 148: Glenmark Pharmaceuticals Ltd. - Key offerings
  • 12.15 Johnson and Johnson
  • Exhibit 149: Johnson and Johnson - Overview
  • Exhibit 150: Johnson and Johnson - Business segments
  • Exhibit 151: Johnson and Johnson - Key news
  • Exhibit 152: Johnson and Johnson - Key offerings
  • Exhibit 153: Johnson and Johnson - Segment focus
  • 12.16 Mereo BioPharma Group Plc
  • Exhibit 154: Mereo BioPharma Group Plc - Overview
  • Exhibit 155: Mereo BioPharma Group Plc - Product / Service
  • Exhibit 156: Mereo BioPharma Group Plc - Key offerings
  • 12.17 Merus N.V.
  • Exhibit 157: Merus N.V. - Overview
  • Exhibit 158: Merus N.V. - Product / Service
  • Exhibit 159: Merus N.V. - Key offerings

13 Appendix

  • 13.1 Scope of the report
  • 13.2 Inclusions and exclusions checklist
  • Exhibit 160: Inclusions checklist
  • Exhibit 161: Exclusions checklist
  • 13.3 Currency conversion rates for US$
  • Exhibit 162: Currency conversion rates for US$
  • 13.4 Research methodology
  • Exhibit 163: Research methodology
  • Exhibit 164: Validation techniques employed for market sizing
  • Exhibit 165: Information sources
  • 13.5 List of abbreviations
  • Exhibit 166: List of abbreviations
Product Code: IRTNTR72677

Exhibits:

  • Exhibits1: Executive Summary - Chart on Market Overview
  • Exhibits2: Executive Summary - Data Table on Market Overview
  • Exhibits3: Executive Summary - Chart on Global Market Characteristics
  • Exhibits4: Executive Summary - Chart on Market by Geography
  • Exhibits5: Executive Summary - Chart on Market Segmentation by Type
  • Exhibits6: Executive Summary - Chart on Market Segmentation by Distribution Channel
  • Exhibits7: Executive Summary - Chart on Incremental Growth
  • Exhibits8: Executive Summary - Data Table on Incremental Growth
  • Exhibits9: Executive Summary - Chart on Vendor Market Positioning
  • Exhibits10: Parent market
  • Exhibits11: Market Characteristics
  • Exhibits12: Offerings of vendors included in the market definition
  • Exhibits13: Market segments
  • Exhibits14: Chart on Global - Market size and forecast 2022-2027 ($ million)
  • Exhibits15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
  • Exhibits16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
  • Exhibits17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)
  • Exhibits18: Historic Market Size - Data Table on Global bispecific antibodies for cancer market 2017 - 2021 ($ million)
  • Exhibits19: Historic Market Size - Type Segment 2017 - 2021 ($ million)
  • Exhibits20: Historic Market Size - Distribution channel Segment 2017 - 2021 ($ million)
  • Exhibits21: Historic Market Size - Geography Segment 2017 - 2021 ($ million)
  • Exhibits22: Historic Market Size - Country Segment 2017 - 2021 ($ million)
  • Exhibits23: Five forces analysis - Comparison between 2022 and 2027
  • Exhibits24: Chart on Bargaining power of buyers - Impact of key factors 2022 and 2027
  • Exhibits25: Bargaining power of suppliers - Impact of key factors in 2022 and 2027
  • Exhibits26: Threat of new entrants - Impact of key factors in 2022 and 2027
  • Exhibits27: Threat of substitutes - Impact of key factors in 2022 and 2027
  • Exhibits28: Threat of rivalry - Impact of key factors in 2022 and 2027
  • Exhibits29: Chart on Market condition - Five forces 2022 and 2027
  • Exhibits30: Chart on Type - Market share 2022-2027 (%)
  • Exhibits31: Data Table on Type - Market share 2022-2027 (%)
  • Exhibits32: Chart on Comparison by Type
  • Exhibits33: Data Table on Comparison by Type
  • Exhibits34: Chart on CD19 or CD3 - Market size and forecast 2022-2027 ($ million)
  • Exhibits35: Data Table on CD19 or CD3 - Market size and forecast 2022-2027 ($ million)
  • Exhibits36: Chart on CD19 or CD3 - Year-over-year growth 2022-2027 (%)
  • Exhibits37: Data Table on CD19 or CD3 - Year-over-year growth 2022-2027 (%)
  • Exhibits38: Chart on CD30 or CD16A - Market size and forecast 2022-2027 ($ million)
  • Exhibits39: Data Table on CD30 or CD16A - Market size and forecast 2022-2027 ($ million)
  • Exhibits40: Chart on CD30 or CD16A - Year-over-year growth 2022-2027 (%)
  • Exhibits41: Data Table on CD30 or CD16A - Year-over-year growth 2022-2027 (%)
  • Exhibits42: Market opportunity by Type ($ million)
  • Exhibits43: Data Table on Market opportunity by Type ($ million)
  • Exhibits44: Chart on Distribution Channel - Market share 2022-2027 (%)
  • Exhibits45: Data Table on Distribution Channel - Market share 2022-2027 (%)
  • Exhibits46: Chart on Comparison by Distribution Channel
  • Exhibits47: Data Table on Comparison by Distribution Channel
  • Exhibits48: Chart on Hospitals - Market size and forecast 2022-2027 ($ million)
  • Exhibits49: Data Table on Hospitals - Market size and forecast 2022-2027 ($ million)
  • Exhibits50: Chart on Hospitals - Year-over-year growth 2022-2027 (%)
  • Exhibits51: Data Table on Hospitals - Year-over-year growth 2022-2027 (%)
  • Exhibits52: Chart on Retail pharmacies - Market size and forecast 2022-2027 ($ million)
  • Exhibits53: Data Table on Retail pharmacies - Market size and forecast 2022-2027 ($ million)
  • Exhibits54: Chart on Retail pharmacies - Year-over-year growth 2022-2027 (%)
  • Exhibits55: Data Table on Retail pharmacies - Year-over-year growth 2022-2027 (%)
  • Exhibits56: Chart on Online - Market size and forecast 2022-2027 ($ million)
  • Exhibits57: Data Table on Online - Market size and forecast 2022-2027 ($ million)
  • Exhibits58: Chart on Online - Year-over-year growth 2022-2027 (%)
  • Exhibits59: Data Table on Online - Year-over-year growth 2022-2027 (%)
  • Exhibits60: Market opportunity by Distribution Channel ($ million)
  • Exhibits61: Data Table on Market opportunity by Distribution Channel ($ million)
  • Exhibits62: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
  • Exhibits63: Chart on Market share by geography 2022-2027 (%)
  • Exhibits64: Data Table on Market share by geography 2022-2027 (%)
  • Exhibits65: Chart on Geographic comparison
  • Exhibits66: Data Table on Geographic comparison
  • Exhibits67: Chart on North America - Market size and forecast 2022-2027 ($ million)
  • Exhibits68: Data Table on North America - Market size and forecast 2022-2027 ($ million)
  • Exhibits69: Chart on North America - Year-over-year growth 2022-2027 (%)
  • Exhibits70: Data Table on North America - Year-over-year growth 2022-2027 (%)
  • Exhibits71: Chart on Europe - Market size and forecast 2022-2027 ($ million)
  • Exhibits72: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
  • Exhibits73: Chart on Europe - Year-over-year growth 2022-2027 (%)
  • Exhibits74: Data Table on Europe - Year-over-year growth 2022-2027 (%)
  • Exhibits75: Chart on Asia - Market size and forecast 2022-2027 ($ million)
  • Exhibits76: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
  • Exhibits77: Chart on Asia - Year-over-year growth 2022-2027 (%)
  • Exhibits78: Data Table on Asia - Year-over-year growth 2022-2027 (%)
  • Exhibits79: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
  • Exhibits80: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
  • Exhibits81: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
  • Exhibits82: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
  • Exhibits83: Chart on US - Market size and forecast 2022-2027 ($ million)
  • Exhibits84: Data Table on US - Market size and forecast 2022-2027 ($ million)
  • Exhibits85: Chart on US - Year-over-year growth 2022-2027 (%)
  • Exhibits86: Data Table on US - Year-over-year growth 2022-2027 (%)
  • Exhibits87: Chart on Ireland - Market size and forecast 2022-2027 ($ million)
  • Exhibits88: Data Table on Ireland - Market size and forecast 2022-2027 ($ million)
  • Exhibits89: Chart on Ireland - Year-over-year growth 2022-2027 (%)
  • Exhibits90: Data Table on Ireland - Year-over-year growth 2022-2027 (%)
  • Exhibits91: Chart on China - Market size and forecast 2022-2027 ($ million)
  • Exhibits92: Data Table on China - Market size and forecast 2022-2027 ($ million)
  • Exhibits93: Chart on China - Year-over-year growth 2022-2027 (%)
  • Exhibits94: Data Table on China - Year-over-year growth 2022-2027 (%)
  • Exhibits95: Chart on Hungary - Market size and forecast 2022-2027 ($ million)
  • Exhibits96: Data Table on Hungary - Market size and forecast 2022-2027 ($ million)
  • Exhibits97: Chart on Hungary - Year-over-year growth 2022-2027 (%)
  • Exhibits98: Data Table on Hungary - Year-over-year growth 2022-2027 (%)
  • Exhibits99: Chart on India - Market size and forecast 2022-2027 ($ million)
  • Exhibits100: Data Table on India - Market size and forecast 2022-2027 ($ million)
  • Exhibits101: Chart on India - Year-over-year growth 2022-2027 (%)
  • Exhibits102: Data Table on India - Year-over-year growth 2022-2027 (%)
  • Exhibits103: Market opportunity by geography ($ million)
  • Exhibits104: Data Tables on Market opportunity by geography ($ million)
  • Exhibits105: Impact of drivers and challenges in 2022 and 2027
  • Exhibits106: Overview on Criticality of inputs and Factors of differentiation
  • Exhibits107: Overview on factors of disruption
  • Exhibits108: Impact of key risks on business
  • Exhibits109: Vendors covered
  • Exhibits110: Matrix on vendor position and classification
  • Exhibits111: ABL Bio Inc. - Overview
  • Exhibits112: ABL Bio Inc. - Product / Service
  • Exhibits113: ABL Bio Inc. - Key offerings
  • Exhibits114: AFFIMED N.V. - Overview
  • Exhibits115: AFFIMED N.V. - Product / Service
  • Exhibits116: AFFIMED N.V. - Key offerings
  • Exhibits117: Akeso Inc. - Overview
  • Exhibits118: Akeso Inc. - Product / Service
  • Exhibits119: Akeso Inc. - Key offerings
  • Exhibits120: Amgen Inc. - Overview
  • Exhibits121: Amgen Inc. - Product / Service
  • Exhibits122: Amgen Inc. - Key offerings
  • Exhibits123: Aptevo Therapeutics Inc. - Overview
  • Exhibits124: Aptevo Therapeutics Inc. - Product / Service
  • Exhibits125: Aptevo Therapeutics Inc. - Key offerings
  • Exhibits126: Astellas Pharma Inc. - Overview
  • Exhibits127: Astellas Pharma Inc. - Product / Service
  • Exhibits128: Astellas Pharma Inc. - Key offerings
  • Exhibits129: Chugai Pharmaceutical Co. Ltd. - Overview
  • Exhibits130: Chugai Pharmaceutical Co. Ltd. - Product / Service
  • Exhibits131: Chugai Pharmaceutical Co. Ltd. - Key offerings
  • Exhibits132: Eli Lilly and Co. - Overview
  • Exhibits133: Eli Lilly and Co. - Product / Service
  • Exhibits134: Eli Lilly and Co. - Key offerings
  • Exhibits135: EPIMAB BIOTHERAPEUTICS INC. - Overview
  • Exhibits136: EPIMAB BIOTHERAPEUTICS INC. - Product / Service
  • Exhibits137: EPIMAB BIOTHERAPEUTICS INC. - Key offerings
  • Exhibits138: F STAR THERAPEUTICS INC. - Overview
  • Exhibits139: F STAR THERAPEUTICS INC. - Product / Service
  • Exhibits140: F STAR THERAPEUTICS INC. - Key offerings
  • Exhibits141: F. Hoffmann La Roche Ltd. - Overview
  • Exhibits142: F. Hoffmann La Roche Ltd. - Business segments
  • Exhibits143: F. Hoffmann La Roche Ltd. - Key news
  • Exhibits144: F. Hoffmann La Roche Ltd. - Key offerings
  • Exhibits145: F. Hoffmann La Roche Ltd. - Segment focus
  • Exhibits146: Glenmark Pharmaceuticals Ltd. - Overview
  • Exhibits147: Glenmark Pharmaceuticals Ltd. - Product / Service
  • Exhibits148: Glenmark Pharmaceuticals Ltd. - Key offerings
  • Exhibits149: Johnson and Johnson - Overview
  • Exhibits150: Johnson and Johnson - Business segments
  • Exhibits151: Johnson and Johnson - Key news
  • Exhibits152: Johnson and Johnson - Key offerings
  • Exhibits153: Johnson and Johnson - Segment focus
  • Exhibits154: Mereo BioPharma Group Plc - Overview
  • Exhibits155: Mereo BioPharma Group Plc - Product / Service
  • Exhibits156: Mereo BioPharma Group Plc - Key offerings
  • Exhibits157: Merus N.V. - Overview
  • Exhibits158: Merus N.V. - Product / Service
  • Exhibits159: Merus N.V. - Key offerings
  • Exhibits160: Inclusions checklist
  • Exhibits161: Exclusions checklist
  • Exhibits162: Currency conversion rates for US$
  • Exhibits163: Research methodology
  • Exhibits164: Validation techniques employed for market sizing
  • Exhibits165: Information sources
  • Exhibits166: List of abbreviations
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!